Treatment for triple-negative breast cancer with sacituzumab govitecan

Xinhuan Wan, Wei Zhu

Sacituzumab Govitecan (SG) is an anti-cancer drug that combines a humanized monoclonal antibody that binds to cancer cells that express the Trophoblast cell surface antigen-2 (Trop-2) with the cytotoxic SN-38 (govitecan) moiety. A marketing authorization for SG as a monotherapy for the treatment of adult patients with Metastatic or unresectable Triple-Negative Breast Cancer (mTNBC) via the buccal route. Although some studies have an in vivo performance, the use of mucoadhesive polymers in buccal medication administration reveals measuring buccal drug penetration and absorption. This review discusses the use of polymers in the production of drug delivery systems (hydrogels, films, and tablets) and presents the outcomes of studies done on how well those systems operate in vivo.